Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) CEO Raju Mohan sold 30,000 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $38.37, for a total transaction of $1,151,100.00. Following the transaction, the chief executive officer now owns 1,512,911 shares of the company’s stock, valued at approximately $58,050,395.07. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Raju Mohan also recently made the following trade(s):
- On Monday, June 5th, Raju Mohan sold 30,000 shares of Ventyx Biosciences stock. The shares were sold at an average price of $34.36, for a total transaction of $1,030,800.00.
- On Friday, May 5th, Raju Mohan sold 30,000 shares of Ventyx Biosciences stock. The shares were sold at an average price of $39.28, for a total transaction of $1,178,400.00.
- On Monday, April 10th, Raju Mohan sold 9,255 shares of Ventyx Biosciences stock. The shares were sold at an average price of $29.01, for a total transaction of $268,487.55.
Ventyx Biosciences Stock Down 6.2 %
Ventyx Biosciences stock opened at $37.82 on Thursday. Ventyx Biosciences, Inc. has a 12-month low of $12.87 and a 12-month high of $47.25. The firm’s 50-day moving average is $35.19 and its two-hundred day moving average is $36.30.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on VTYX shares. Credit Suisse Group started coverage on shares of Ventyx Biosciences in a report on Wednesday, June 14th. They issued an “outperform” rating and a $63.00 price target for the company. Oppenheimer cut their price target on shares of Ventyx Biosciences from $65.00 to $62.00 and set an “outperform” rating for the company in a report on Friday, March 24th. Wells Fargo & Company assumed coverage on shares of Ventyx Biosciences in a research note on Monday, March 20th. They issued an “overweight” rating and a $77.00 price objective on the stock. Finally, 500.com reissued a “reiterates” rating on shares of Ventyx Biosciences in a research note on Friday, May 12th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Ventyx Biosciences presently has an average rating of “Buy” and a consensus price target of $55.40.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of VTYX. FMR LLC lifted its holdings in shares of Ventyx Biosciences by 348.8% during the 1st quarter. FMR LLC now owns 7,604,341 shares of the company’s stock worth $254,745,000 after acquiring an additional 5,909,854 shares during the period. Avidity Partners Management LP purchased a new position in shares of Ventyx Biosciences during the 4th quarter worth about $42,135,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Ventyx Biosciences by 163.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,805,574 shares of the company’s stock worth $59,205,000 after acquiring an additional 1,120,232 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of Ventyx Biosciences during the 4th quarter worth about $15,412,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Ventyx Biosciences during the 1st quarter worth about $14,184,000.
About Ventyx Biosciences
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Featured Articles
- Five stocks we like better than Ventyx Biosciences
- 3 Russell 2000 Stocks to Buy as Small-Caps Make a Comeback
- These Banks Are Boosting Dividends After Safe Stress Tests
- Three (3) Stocks Under $10 That Insiders Are BuyingÂ
- 3 Cash-Rich Defensive Companies Making Investors Rich
- Can Valero Energy Corporation Rise To New Highs In 2023?
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
